News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
291,335 Results
Type
Article (17815)
Company Profile (37)
Press Release (273483)
Multimedia
Podcasts (8)
Webinars (7)
Section
Business (81306)
Career Advice (162)
Deals (12561)
Drug Delivery (28)
Drug Development (37266)
Employer Resources (20)
FDA (5310)
Job Trends (4185)
News (135504)
Policy (10451)
Tag
Academia (647)
Accelerated approval (3)
Adcomms (1)
Allergies (46)
Alliances (22112)
ALS (42)
Alzheimer's disease (435)
Antibody-drug conjugate (ADC) (72)
Approvals (5346)
Artificial intelligence (126)
Autoimmune disease (19)
Automation (8)
Bankruptcy (82)
Best Places to Work (3651)
Biosimilars (30)
Biotechnology (32)
Bladder cancer (52)
Brain cancer (8)
Breast cancer (165)
Cancer (1345)
Cardiovascular disease (85)
Career advice (138)
Career pathing (2)
CAR-T (100)
Cell therapy (223)
Cervical cancer (10)
Clinical research (30760)
Collaboration (443)
Compensation (217)
Complete response letters (6)
COVID-19 (1917)
CRISPR (22)
C-suite (128)
Cystic fibrosis (48)
Data (1346)
Depression (16)
Diabetes (116)
Diagnostics (2103)
Digital health (8)
Diversity (1)
Diversity, equity & inclusion (5)
Drug discovery (42)
Drug pricing (20)
Drug shortages (5)
Duchenne muscular dystrophy (32)
Earnings (23580)
Editorial (7)
Employer branding (2)
Employer resources (18)
Events (51748)
Executive appointments (441)
FDA (5964)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (2)
Funding (433)
Gene editing (47)
Generative AI (5)
Gene therapy (143)
GLP-1 (209)
Government (1354)
Grass and pollen (4)
Guidances (60)
Healthcare (4897)
Huntington's disease (11)
IgA nephropathy (21)
Immunology and inflammation (56)
Indications (15)
Infectious disease (1995)
Inflammatory bowel disease (62)
Inflation Reduction Act (2)
Influenza (37)
Intellectual property (43)
Interviews (30)
IPO (4938)
IRA (6)
Job creations (880)
Job search strategy (124)
Kidney cancer (5)
Labor market (2)
Layoffs (91)
Legal (2369)
Liver cancer (39)
Lung cancer (183)
Lymphoma (136)
Machine learning (1)
Management (5)
Manufacturing (116)
MASH (39)
Medical device (2795)
Medtech (2795)
Mergers & acquisitions (7976)
Metabolic disorders (266)
Multiple sclerosis (56)
NASH (10)
Neurodegenerative disease (43)
Neuropsychiatric disorders (10)
Neuroscience (671)
NextGen: Class of 2025 (1571)
Non-profit (612)
Obesity (111)
Opinion (114)
Ovarian cancer (48)
Pain (48)
Pancreatic cancer (47)
Parkinson's disease (63)
Partnered (6)
Patents (81)
Patient recruitment (52)
Peanut (25)
People (33571)
Pharmaceutical (8)
Pharmacy benefit managers (3)
Phase I (10351)
Phase II (14204)
Phase III (9411)
Pipeline (754)
Policy (18)
Postmarket research (1008)
Preclinical (3732)
Press Release (16)
Prostate cancer (63)
Psychedelics (4)
Radiopharmaceuticals (63)
Rare diseases (171)
Real estate (1714)
Recruiting (9)
Regulatory (7647)
Reports (8)
Research institute (614)
Resumes & cover letters (20)
Rett syndrome (4)
RNA editing (3)
RSV (24)
Schizophrenia (27)
Series A (68)
Series B (94)
Service/supplier (2)
Sickle cell disease (24)
Special edition (3)
Spinal muscular atrophy (54)
Sponsored (8)
Startups (1892)
Stomach cancer (4)
Supply chain (32)
Tariffs (6)
The Weekly (8)
Vaccines (379)
Venture capitalists (16)
Weight loss (53)
Women's health (12)
Date
Today (152)
Last 7 days (457)
Last 30 days (1584)
Last 365 days (15427)
2025 (6003)
2024 (14146)
2023 (13781)
2022 (19280)
2021 (22408)
2020 (19414)
2019 (10455)
2018 (7945)
2017 (14273)
2016 (16848)
2015 (21248)
2014 (15945)
2013 (13441)
2012 (13882)
2011 (13558)
2010 (11844)
Location
Africa (286)
Alabama (16)
Arizona (65)
Arkansas (7)
Asia (18052)
Australia (2679)
California (3227)
Canada (932)
China (243)
Colorado (152)
Connecticut (167)
Delaware (107)
Europe (43264)
Florida (362)
Georgia (101)
Idaho (14)
Illinois (289)
India (10)
Indiana (78)
Iowa (4)
Japan (99)
Kansas (41)
Kentucky (11)
Louisiana (1)
Maine (10)
Maryland (343)
Massachusetts (2456)
Michigan (68)
Minnesota (127)
Missouri (37)
Montana (10)
Nebraska (3)
Nevada (43)
New Hampshire (14)
New Jersey (867)
New Mexico (5)
New York (855)
North Carolina (376)
North Dakota (3)
Northern California (1452)
Ohio (75)
Oklahoma (3)
Oregon (12)
Pennsylvania (546)
Puerto Rico (4)
Rhode Island (12)
South America (527)
South Carolina (5)
Southern California (1146)
Tennessee (35)
Texas (501)
United States (11199)
Utah (52)
Virginia (77)
Washington D.C. (25)
Washington State (318)
West Virginia (1)
Wisconsin (49)
291,335 Results for "cergentis b v".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES LAUNCH OF AUTHORIZED GENERIC OF Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension)
April 25, 2025
·
3 min read
Press Releases
Pharming Technologies B.V. increases its ownership in Abliva AB (publ) to 92.70 percent
February 21, 2025
·
11 min read
Press Releases
MilliporeSigma Acquires HUB Organoids Holding B.V., Expands Next-Gen Biology Portfolio
January 7, 2025
·
3 min read
Press Releases
MilliporeSigma to Acquire HUB Organoids Holding B.V., Advancing Next Generation Biology Portfolio
December 17, 2024
·
5 min read
Pharm Country
Amring Pharmaceuticals Inc. Announces Name Change to Nordic Pharma, Inc. Under New Nordic Group, B.V. Ownership
Amring Pharmaceuticals Inc. (“Amring”) announces its name change to Nordic Pharma, Inc. on March 4, 2024, following the change in ownership of the company from SEVER Life Sciences, B.V. to Nordic Group, B.V., a subsidiary of SEVER Life Sciences B.V., which occurred on June 1, 2023.
March 4, 2024
·
3 min read
Press Releases
NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), PRESENTING PATIENT DATA AND PATIENT EXPERIENCE STUDY FOR LACRIFILL® CANALICULAR GEL, A NOVEL THERAPY FOR DRY EYE, AT THE AMERICAN SOCIETY OF CATARACT AND REFRACTIVE SURGERY ANNUAL MEETING
April 24, 2025
·
4 min read
Press Releases
Vivoryon Therapeutics N.V. Signs Financing Agreement for up to EUR 15 Million
April 24, 2025
·
5 min read
Approvals
Sanofi, Alnylam Win First RNAi Approval for Hemophilia A and B
Unlike other hemophilia therapies, Qfitlia is indicated for both hemophilia A and B, and can be given in patients regardless of the presence of neutralizing antibodies against clotting factor VIII or IX.
March 31, 2025
·
2 min read
·
Tristan Manalac
Neuroscience
GSK Dives Deeper Into Neuro With $2.5B+ ABL Bio Pact
GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier.
April 7, 2025
·
2 min read
·
Tristan Manalac
Deals
Clade Therapeutics Announces the Acquisition of Gadeta B.V.
Clade Therapeutics today announced that it has completed the acquisition of Gadeta B.V.
October 2, 2023
·
4 min read
1 of 29,134
Next
